最新一期业绩显示，2025年一季报，公司实现营业收入4.82亿元，同比-1.92%；净利润1.43亿元，同比 2.74%，销售毛利率48.92%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13奕瑞科技37.8038.113.91177.29亿行业平均 52.0649.724.58107.83亿行业中值37.2238.112.4752.18亿1九安医疗10.3010.410.81173.78亿2英科医疗 10.8811.730.97171.88亿3新华医疗14.4413.391.1892.58亿4振德医疗15.4114.530.9855.95亿5奥美医疗 15.5115.201.5956.04亿6山东药玻15.6115.661.79147.65亿7康德莱16.0916.111.3334.68亿8维力医疗 16.6017.261.9537.87亿9奥泰生物16.6317.541.3453.04亿10九强生物16.7915.612.0683.13亿11安杰思 17.5917.802.1352.22亿12三鑫医疗18.9718.983.1243.15亿 来源：金融界 7月11日，奕瑞科技今日收盘88.5 ...

Group 1 - The core viewpoint of the news is that Yirui Technology's stock performance and financial metrics indicate a stable position within the medical device industry, despite a slight decline in revenue [1] - As of July 1, Yirui Technology's closing price was 88.5 yuan, with a PE ratio of 37.78 times and a total market capitalization of 17.719 billion yuan [1] - The average PE ratio for the medical device industry is 51.70 times, with a median of 37.36 times, positioning Yirui Technology at the 77th rank within the industry [1][2] Group 2 - Yirui Technology reported a revenue of 482 million yuan for Q1 2025, reflecting a year-on-year decrease of 1.92%, while net profit was 143 million yuan, showing a year-on-year increase of 2.74% [1] - The company's gross profit margin stands at 48.92% [1] - As of March 31, 2025, Yirui Technology had 5,745 shareholders, a decrease of 883 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

6月26日，奕瑞科技今日收盘88.77元，下跌1.31%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到37.90倍，总市值177.73亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.45倍，行业中值35.92倍，奕瑞科技排 名第80位。 最新一期业绩显示，2025年一季报，公司实现营业收入4.82亿元，同比-1.92%；净利润1.43亿元，同比 2.74%，销售毛利率48.92%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13奕瑞科技37.9038.213.92177.73亿行业平均 49.4547.484.57105.42亿行业中值35.9237.582.3948.69亿1英科医疗9.6210.370.86152.00亿2九安医疗 10.1110.220.80170.60亿3新华医疗14.2313.191.1691.24亿4奥美医疗14.7414.451.5253.26亿5康德莱 15.1015.111.2532.54亿6振德医疗15.5614.670.9956.49亿7山东药玻15.7915.831.81149.31亿8维力医疗 15.9016.531.8 ...

Core Viewpoint - The company, Miaokelan Duo, has shown significant growth in its cheese segment, particularly in the family dining and catering industrial series, following the integration with Mengniu Cheese, indicating a positive trend in profitability driven by high-margin products and cost reductions from domestic raw material substitutions [1][2]. Group 1: Company Performance - In the first quarter, the ready-to-eat nutrition series achieved single-digit growth, while the family dining series and catering industrial series saw over 30% year-on-year growth [1]. - The high-margin cheese business's increasing share and cost reductions from domestic raw materials have been key drivers for the improvement in profitability [1]. - The family dining cheese series has expanded its sales scope and consumption scenarios, targeting a broader demographic beyond just children's snacks [1]. Group 2: Strategic Initiatives - The company plans to focus on three strategic areas: growth in cheese sticks, breaking into adult markets, and B2B breakthroughs [3]. - The company aims to align with the "Healthy China 2030" initiative, responding to consumer demands for reduced fat, sugar, and salt, while increasing micronutrient intake through health-oriented product development [3]. - The company intends to integrate online and offline resources, leveraging both B2B and B2C brand advantages, and enhancing key account channels while penetrating new retail models [3]. Group 3: Industry Outlook - The cheese industry in China is poised for new growth opportunities, with rapid market expansion expected as consumer awareness and acceptance of cheese increase [3]. - Experts suggest that there is significant potential for growth in per capita dairy consumption in China, with a focus on increasing the proportion of high-value products like cheese [3].